Airway and systemic inflammation and decline in lung function in patients with COPD

Gavin C Donaldson, Terence A R Seemungal, Irem S Patel, Angshu Bhowmik, Tom M A Wilkinson, John R Hurst, Peter K Maccallum, Jadwiga A Wedzicha, Gavin C Donaldson, Terence A R Seemungal, Irem S Patel, Angshu Bhowmik, Tom M A Wilkinson, John R Hurst, Peter K Maccallum, Jadwiga A Wedzicha

Abstract

Study objectives: Patients with COPD experience lower airway and systemic inflammation, and an accelerated decline in FEV1. There is no evidence on whether this inflammation changes over time, or if it is associated with a faster decline in FEV1.

Patients and design: A cohort of 148 COPD patients (100 men) was monitored daily for a median of 2.91 years (interquartile range [IQR], 2.1 to 4.8). At recruitment, median age was 68.5 years (IQR, 62.5 to 73.6) and FEV1 as percentage of predicted (FEV1%Pred) was 38.5% (IQR, 27.7 to 50.3).

Results: During the study, the patients experienced 1,389 exacerbations, a median of 2.52/yr (IQR, 1.48 to 3.96) and FEV1 declined by 40.2 mL/yr or as FEV1%Pred by 1.5%/yr. Concerning inflammatory markers, sputum interleukin (IL)-6 rose by 9 pg/mL/yr, sputum neutrophil count rose by 1.64 x 10(6) cells per gram sputum per year, an plasma fibrinogen rose by 0.10 g/L/yr (all p < 0.05). Patients with frequent exacerbations (> or = 2.52/yr) had a faster rise over time in plasma fibrinogen and sputum IL-6 of 0.063 g/L/yr (p = 0.046, n = 130) and 29.5 pg/mL/yr (p < 0.001, n = 98), respectively, compared to patients with infrequent exacerbations (< 2.52/yr). Using the earliest stable (nonexacerbation) measured marker, patients whose IL-6 exceeded the group median had a faster FEV1%Pred decline of 0.42%/yr (p = 0.018). Similarly, a high neutrophil count or fibrinogen were associated with a faster FEV1%Pred decline of 0.97%/yr (p = 0.001) and 0.40%/yr (p = 0.014), respectively.

Conclusions: In COPD, airway and systemic inflammatory markers increase over time; high levels of these markers are associated with a faster decline in lung function.

Figures

Figure 1
Figure 1
Mean stable (exacerbation-free) sputum IL-6, sputum neutrophil count, and plasma fibrinogen measured over 4-month periods, over the 7.3-year period of this study, from October 1995. Bars are 2 × SE. Lines are from a simple linear regression through these data.
Figure 2
Figure 2
Mean FEV1%Pred in 4-month periods for low plasma fibrinogen and sputum IL-6 group patients (circles and thin line) and for high plasma fibrinogen and sputum IL-6 group patients (squares and thick line) against time from recruitment of each patient. Bars are 2 × SE. Error bars increase in size with time, as not all patients participated in the study for 7.33 years. No adjustment has been made for covariates.
Figure 3
Figure 3
Mean plasma fibrinogen levels over 4-month intervals in infrequent (circles and thin-line exacerbators (

References

    1. Murrey CJL, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Health Study. Science. 1996;274:740–743.
    1. Thomason M, Strachan DP. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease? Thorax. 2000;5:785–788.
    1. Anthonisen NR, Connett JE, Kiley JP. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;16:1539–1541.
    1. Donaldson GC, Seemungal TAR, Bhowmik A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852.
    1. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:358–364.
    1. Di Stefano A, Capelli A, Lusuardi M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277–1285.
    1. Stãnescu D, Sanna A, Veriter C. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51:267–271.
    1. Bhowmik A, Seemungal TAR, Sapsford RJ. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120.
    1. Wedzicha JA, Seemungal TAR, Mac Callum PK. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84:210–215.
    1. Dahl M, Tybjaerg-Hansen A, Vestbo J. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008–1011.
    1. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289.
    1. Hill AT, Campbell EJ, Hill SL. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109:288–295.
    1. Patel IS, Seemungal TA, Wilks M. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759–764.
    1. Wilkinson TMA, Patel IS, Wilks M. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–1095.
    1. Seemungal T, Harper-Owen R, Bhowmik A. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–1623.
    1. Bhowmik A, Seemungal TA, Sapsford RJ. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax. 1998;53:953–956.
    1. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957;17:237–246.
    1. Zalacain R, Sobradillo V, Amilibia J. Predisposing factors for bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J. 1999;13:343–348.
    1. Seemungal TAR, Donaldson GC, Bhowmik A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613.
    1. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect. 1993;111:143–156.
    1. Isaacs D. Oxford University Press; Oxford, UK: 1996. Respiratory tract viruses; p. 338. (Oxford textbook of medicine). Weatherall, DJ Ledingham, JGG Warrell, DA eds.
    1. Edward LJ. Modern statistical techniques for the analysis of longitudinal data in biomedical research. Pediatr Pulmonol. 2000;30:330–334.
    1. Alessandri C, Basili S, Violi F. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost. 1994;72:343–346.
    1. Meade TW, Ruddock V, Stirling Y. Fibrinolytic activity, clotting factors and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;324:1076–1079.
    1. Short K, Nair R. The effect of age on protein metabolism. Curr Opin Clin Nutr Metab Care. 2000;3:39–44.
    1. Danesh J, Collins R, Appleby P. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease. JAMA. 1998;279:1477–1482.
    1. Lange P, Nyboe J, Appleyard M. Spirometric findings and mortality in never smokers. J Clin Epidemiol. 1990;43:867–873.
    1. Hole DJ, Watt GCM, Davey-Smith G. Impaired lung function and mortality risk in men and women: findings from the Renfew and Paisley prospective population study. BMJ. 1996;313:711–715.
    1. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519.
    1. Eid AA, Ionescu AA, Nixon LS. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414–1418.
    1. De Godoy I, Donahoe M, Calhoun WJ. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1994;150:1453–1455.
    1. Wouters EF. Chronic obstructive pulmonary disease: 5. Systemic effects of COPD. Thorax. 2002;57:1067–1070.
    1. Dentener MA, Creutzberg EC, Schols AM. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001;56:721–726.
    1. Spruit MA, Gosselink R, Troosters T. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58:752–756.
    1. Vernooy JH, Kucukaycan M, Jacos JA. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1218–1224.
    1. Turato G, Zuin R, Miniati M. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166:105–110.
    1. Jones PW, Willits LR, Burge PS. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73.
    1. Sutherland ER, Allmers H, Ayas NT. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937–941.
    1. Fletcher CM, Peto R, Tinker CM. Oxford University Press; Oxford, UK: 1976. (The natural history of chronic bronchitis and emphysema).
    1. Soler N, Ewig S, Torres A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14:1015–1022.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe